April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Theoretical assessment for the gene therapy of gelatinous drop-like corneal dystrophy
Author Affiliations & Notes
  • Satoshi Kawasaki
    Ophthalmology, Osaka University, Suita, Japan
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Koji Kitazawa
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Katsuhiko Shinomiya
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Mina Nakatsukasa
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Motokazu Tsujikawa
    Ophthalmology, Osaka University, Suita, Japan
  • Akira Matsuda
    Ophthalmology, Juntendo University, Tokyo, Japan
  • Akira Murakami
    Ophthalmology, Juntendo University, Tokyo, Japan
  • Kohji Nishida
    Ophthalmology, Osaka University, Suita, Japan
  • Shigeru Kinoshita
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Footnotes
    Commercial Relationships Satoshi Kawasaki, None; Koji Kitazawa, None; Katsuhiko Shinomiya, None; Mina Nakatsukasa, None; Motokazu Tsujikawa, None; Akira Matsuda, None; Akira Murakami, None; Kohji Nishida, None; Shigeru Kinoshita, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 2201. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Satoshi Kawasaki, Koji Kitazawa, Katsuhiko Shinomiya, Mina Nakatsukasa, Motokazu Tsujikawa, Akira Matsuda, Akira Murakami, Kohji Nishida, Shigeru Kinoshita; Theoretical assessment for the gene therapy of gelatinous drop-like corneal dystrophy. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2201. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Gelatinous drop-like corneal dystrophy (GDLD) is caused by the biallelic loss of function mutation of the TACSTD2 gene. There is currently no good fundamental therapy for this disease and it is assumed that gene therapy would be ideal for this disease. In this study, we performed a theoretical assessment for this issue using an immortalized corneal epithelial cells from a GDLD patient.

Methods: Immortalized corneal epithelial cells were established from a GDLD (p.Gln118X) patient (iHCE_GDLD cells) as well as from a conjunctivochalasis (wild type TACSTD2) patient (iHCE_normal cells) (I). Lentiviral vector harboring the wild type TACSTD2 gene was infected to the immortalized corneal epithelial cells from a GDLD patient. Change in the expression level and the subcellular localization of tight-junction-related proteins (ZO-1, claudin 1, 4 and 7, and occuludin) as well as epithelial barrier function was assessed before and after the infection. Epithelial barrier function was also assessed. for the mixture of the iHCE_GDLD cells and the iHCE_normal cells with various ratio in order to clarify the requisite gene introduction efficiency for the treatment of GDLD.

Results: Prominent decrease in the expression level as well as the apparent change in the subcellular localization of the claudin 1 and 7 proteins was observed in the iHCE_GDLD cells compared to the iHCE_normal. After the infection of the lentiviral vector harboring the wild type TACSTD2 gene, these pathological differences were almost completely normalized. However, epithelial barrier function was not normalized after the infection, just showing a faint improvement. From the epithelial barrier function experiment using a mixture of the iHCE_GDLD cells and the iHCE_normal cells, it was clarified that 95% gene introduction efficiency was needed for 90% improvement and 80% gene introduction efficiency was needed for 50% improvement in the epithelial barrier function.

Conclusions: Gene therapy is really an efficient treatment for GDLD, but the requisite gene introduction efficiency is quite high for the achievement of clinically-sufficient treatment level.

Keywords: 538 gene transfer/gene therapy • 482 cornea: epithelium  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×